Lung Cancer Screening Cost Effectiveness in Medicare Population
$18,452 per QALY
| Estimates Impact of Lung Cancer Screening on Life-Years Saved and Cost per Life-Year Saved,* Using Base-Case (I-ELCAP Data for Screening Results) | |||
|---|---|---|---|
| Impact of Screening | Total | Male | Female |
Cumulative life-years saved, yrs |
2,825,652 |
1,313,423 |
1,512,229 |
Lead-time correction, yrs |
568,599 |
276,563 |
292,036 |
True life-years saved (0-yr lead time life-year saved, yrs |
2,257,053 |
1,036,860 |
1,220,193 |
Cumulative extra cost, $ |
41,647,811,614 |
23,241,454,701 |
18,406,356,913 |
Cost per additional life-year, $ |
18,452 |
22,415 |
15,065 |
| Patients diagnosed with lung cancer in 2014 | |||
Average life expectancy without screening, yrs |
3.07 |
2.81 |
3.36 |
Avergage life expectancy with screening (with no lead time), yrs |
7.01 |
6.30 |
7.81 |
Avergage increased life span because of screening, yrs |
3.94 |
3.49 |
4.47 |
*Life-years saved and cost are for patients with cancer aged 55-110 years.
I-ELCAP indicates International Early Lung Cancer Action Program.
Source: Authors' analysis.